Product image of Rubraca 250mg (Rucaparib) 250mg Tablet supplied by GNH India

Rubraca 250mg

Active Ingredient:
Rucaparib
Form:
Tablet
Brand:
Rubraca
Origin:
Germany

Rubraca 250mg (Rucaparib Tablet) 250mg

Rubraca 250mg (Rucaparib) tablets are prescribed for cancer treatment, specifically targeting certain genetic mutations. This oral therapy is used in maintenance therapy for ovarian cancer. Always consult a healthcare provider for suitability and dosing.

Strength

250mg

Pack Size

60s

Storage

Ambient

Manufacturer / TM Owner

Clovis Oncology Germany GmbH

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

Indications & Clinical Uses

  • Rubraca 250mg (Rucaparib) is a PARP inhibitor used in the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is prescribed for patients who have responded to platinum-based chemotherapy and have a BRCA mutation or homologous recombination deficiency. This medication helps delay cancer progression by interfering with cancer cell repair mechanisms.

Side Effects

  • Rubraca 250mg tablets may cause mild to moderate nausea, fatigue, or changes in taste. Some users report digestive discomfort or reduced appetite during treatment. These effects vary by individual and are typically temporary. Regular monitoring and supportive care can help manage them.

Precautions & Warnings

  • Store Rubraca 250mg tablets at room temperature in a dry place away from moisture and heat. Keep the medication in its original packaging until ready to use. Avoid crushing, splitting, or chewing the tablets. Always handle with care and follow local disposal guidelines for unused or expired medication.

Avoid Interactions

  • Rubraca 250mg may interact with strong CYP3A inhibitors or inducers, which can affect its blood levels. Grapefruit products should be avoided due to potential interaction risks. Inform your healthcare provider about all medications, supplements, and herbal products you are taking to assess possible interactions.

Frequently Asked Questions

Rubraca 250mg is used in the maintenance treatment of recurrent ovarian cancer in patients with BRCA mutations or homologous recombination deficiency.

Rubraca 250mg tablets are taken orally, usually twice daily with or without food, as prescribed by a healthcare provider.

Common side effects may include nausea, fatigue, changes in taste, and digestive discomfort.

Consult your doctor before combining Rubraca 250mg with other medications, as interactions may occur.

No, Rubraca 250mg requires a prescription and should only be used under medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Rucaparib

Nuparp 300mg

Nuparp 300mg

300mg Tablet
Nuprap

Nuprap

300mg Tablet
Rubraca

Rubraca

200mg Tablet

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT